Please assess the completion status of the following clinical trial:

Trial Title: Standard Bupivacaine vs Liposomal Bupivacaine in Colorectal Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Undergoing elective colectomy by surgeons of Fairfax Colon and Rectal Surgery~Exclusion Criteria:~* Allergic to local anesthetics~* Unable to provide consent~* Pregnant~* On opioids at home chronically (Patients previously on a regular opioid regimen would need to be opioid-free for a period of 1 year for inclusion in the study)~* Undergoing emergent operations~* Undergoing loop ileostomy reversal~* Undergoing abdominoperineal resection, pelvic exenteration, or perineal rectal prolapse repairs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard Bupivacaine (Type: ACTIVE_COMPARATOR): Standard (0.25% bupivacaine) bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
- Bupivacaine Liposome (Type: EXPERIMENTAL): Liposomal bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.

Based on this trial design, predict the completion outcome and termination type (if applicable).